ライフサイエンスコーパス: sphingolipid

1 embrane microdomains enriched in sterols and sphingolipids.

2 been a steadily increasing interest in plant sphingolipids.

3 o all major self-phospholipids but absent in sphingolipids.

4 including ceramide phosphoinositol and deoxy-sphingolipids.

5 than 130-fold increase in ceramide and other sphingolipids.

6 etry for autophagy, apoptosis, and bioactive sphingolipids.

7 abnormal accumulation of ceramides and other sphingolipids.

8 y for low-abundance glycerophospholipids and sphingolipids.

9 backbone of ceramides and other predominant sphingolipids.

10 disease resulting in tissue accumulation of sphingolipids.

11 , which requires elevated levels of membrane sphingolipids.

12 -galactose from galactosylceramide and other sphingolipids.

13 brane platforms replete with cholesterol and sphingolipids.

14 t striking changes seen within subclasses of sphingolipids.

15 cids, deprotonated glycerophospholipids, and sphingolipids.

16 east, including one causing PCCA2, result in sphingolipid abnormalities and impaired cell growth that

17 lgi compartment, which may contribute to the sphingolipid abnormalities.

18 terized decreased sphingoid base and complex sphingolipid accumulation and ameliorated autophagic def

19 k, we examined the cause for sphingosine and sphingolipid accumulation in multiple cellular models of

20 either immune cells or tissue, caused local sphingolipid accumulation leading to a dichotomic develo

21 Additionally, NPC disease results in sphingolipid accumulation, yet it is unique among the sp

22 Low native T1 in Fabry disease represents sphingolipid accumulation; late gadolinium enhancement w

23 products such as short-chain fatty acids and sphingolipids also influence immune responses.

24 ts a potential increase in the metabolism of sphingolipids, an essential molecular signal for bacteri

25 Targeting SET with a sphingolipid analog drug fingolimod (FTY720) or ceramide

26 sing the cellular stress model evoked by the sphingolipid analog drug FTY720, we show that formation

27 ies make LDA broadly applicable to automated sphingolipid analysis, especially in high-throughput set

28 s-resolved collision cross sections (CCS) of sphingolipid and glycerophospholipid species.

29 high-throughput metabolic data and show that sphingolipid and purine metabolism are significantly per

30 between increased abundance of hydroxylated sphingolipids and abnormal rhabdomeric growth.

31 iacyl-glycerophospholipids and a decrease in sphingolipids and acyl-alkyl-glycerophospholipids among

32 up-regulation of AAs and down-regulation of sphingolipids and acyl-alkyl-glycerophospholipids were s

33 2) to explore the relationship between serum sphingolipids and CAD, using unbiased machine learning t

34 Lower levels of sphingolipids and ceramides and other metabolomic altera

35 unsaturation level, cis/trans isomer ratio, sphingolipids and cholesterol levels in live cells-with

36 model membrane systems that contain abundant sphingolipids and cholesterol.

37 ts the homeostasis of both glycerolipids and sphingolipids and is important for cellular expansion du

38 ent mice were restored by supplementing with sphingolipids and pharmacologically inhibiting ER stress

39 criminate between two major types of lipids, sphingolipids and phospholipids, but were broadly cross-

40 In the past few decades, sphingolipids and sphingolipid metabolites have gained a

41 nephropathies have described accumulation of sphingolipids and sphingolipid metabolites, and it has b

42 nome-wide association studies of circulating sphingolipids and the China Health and Nutrition Survey

43 We investigated the role of sphingolipids and the lipid-modifying enzyme sphingomyel

44 ch were consistently enriched in fatty acyl, sphingolipid, and glycerophospholipid metabolism.

45 We performed transcriptomic, sphingolipid, and protein analyses to evaluate sphingoli

46 olipids, 16% for cholesteryl esters, 15% for sphingolipids, and 9% for hexoses.

47 ut asthma, quantified plasma and whole-blood sphingolipids, and assessed sphingolipid de novo synthes

48 allergic childhood asthma, lower whole-blood sphingolipids, and asthma-risk 17q21 genotypes.

49 anolamines, lysophosphatidylcholines (LPCs), sphingolipids, and cholesteryl esters all showed delayed

50 nsing by glycosylinositol phosphorylceramide sphingolipids, and drought sensing by the specific calci

51 s considered to exhibit bioactive functions, sphingolipids are a class of molecules that have shown r

52 d over recent years it has become clear that sphingolipids are a key player in these responses.

53 Sphingolipids are also involved in multiple cellular and

54 centrations are similar for MCC and MCP, but sphingolipids are enriched in MCP.

55 Although sphingolipids are implicated in atherosclerosis as both

56 Sphingolipids are important components of cellular membr

57 Besides receptor function, bioactive sphingolipids are increasingly recognized as potent regu

58 Sphingolipids are membrane and bioactive lipids that are

59 Sphingolipids are not universally present in all three d

60 bioactive lipids such as diacylglycerols and sphingolipids are now thought to play an important role.

61 Sphingolipids are recognised as critical components of t

62 Sphingolipids are structural membrane components and imp

63 Sphingolipids are substrates of ABC proteins in cell sig

64 holipids are predominantly non-hydroxylated, sphingolipids are typically dihydroxylated.

65 sults suggest the potential utility of serum sphingolipids as cholesterol-independent markers of risk

66 the integrity of lipid rafts, which include sphingolipids as key components.

67 e framework for the development of promising sphingolipid-based therapies against this virus-associat

68 with sulfatides resemble those described for sphingolipid-binding in other proteins, suggesting that

69 In the context of emerging evidence linking sphingolipid biology with cardiovascular pathophysiology

70 Sphingolipid biosynthesis generates lipids for membranes

71 Disruption of sphingolipid biosynthesis in various cell types, includi

72 Using lipidomic analysis, we described a sphingolipid biosynthesis pathway and revealed a variety

73 leles within the 17q21 locus affecting ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) expressio

74 toyltransferase (SPT) to negatively regulate sphingolipid biosynthesis, a reversible process critical

75 have been known to be negative regulators of sphingolipid biosynthesis, act as selective autophagy re

76 the first and rate-limiting step in de novo sphingolipid biosynthesis.

77 evels of ceramide, indicative of unregulated sphingolipid biosynthesis.

78 The plant sphingolipid biosynthetic enzyme, inositol phosphorylcer

79 Sptlc2 deficiency reduced sphingolipid biosynthetic flux and led to prolonged acti

80 The screen identified several genes in the sphingolipid biosynthetic pathway that are required for

81 duced expression of several key genes in the sphingolipid biosynthetic pathway.

82 vels of glucosylceramide, a vital intestinal sphingolipid, both in mice and in colon organoids (colon

83 (SPT) catalyses the de novo biosynthesis of sphingolipids but also produces noncanonical 1-deoxysphi

84 Many bacteria and archaea do not produce sphingolipids but they are ubiquitous in eukaryotes and

85 a from the Bacteroidetes phylum also produce sphingolipids, but the impact of these metabolites on ho

86 hibition of the de novo synthesis pathway of sphingolipids by inhibiting serine palmitoyl transferase

87 t impact on p24 dimerization, binding of the sphingolipid can clearly control dimerization of p24 in

88 o showed upregulated expression of genes for sphingolipid catabolic enzymes, pointing to additional m

89 missorting of lysosomal proteins, including sphingolipid catabolism enzymes, to the Golgi compartmen

90 The sphingolipid ceramide 1-phosphate (C1P) directly binds t

91 particularly responsive to the pro-apoptotic sphingolipid ceramide and that this response is strictly

92 Additionally, the sphingolipid ceramide redistributes to ZIKV replication

93 Sphingolipids, cholesteryl esters, and phospholipids wer

94 Sphingolipids compose a lipid family critical for membra

95 d it has become clear that the intracellular sphingolipid composition of renal cells is an important

96 We analyzed their glycerolipid and sphingolipid compositions and quantified interaction kin

97 Sphingolipids constitute a heterogeneous lipid category

98 Sphingolipids constitute a significant fraction of cellu

99 s from Ahr knockout mice displayed decreased sphingolipid content as well as significantly reduced ex

100 settes had perturbations in glycerolipid and sphingolipid content.

101 ginations enriched with high cholesterol and sphingolipid content; they also contain caveolin protein

102 and whole-blood sphingolipids, and assessed sphingolipid de novo synthesis in peripheral blood cells

103 ORMDL3 inhibits sphingolipid de novo synthesis.

104 l health, we colonized germ-free mice with a sphingolipid-deficient Bacteroides thetaiotaomicron stra

105 of mutations in the enzymes responsible for sphingolipid degradation.

106 candidate retinol isomerase of this pathway, sphingolipid delta4 desaturase 1 (Des1).

107 eir metabolic derivatives in a wide array of sphingolipid-dependent cellular processes with the spati

108 We performed a genome-wide CRISPRi screen in sphingolipid-depleted human cells and identified hyperse

109 r, the relative and separate contribution of sphingolipid deterioration in inflammation versus carcin

110 dosomal/lysosomal compartments and-common to sphingolipid diseases-abnormal endocytic trafficking of

111 e report DEGS1 dysfunction as the cause of a sphingolipid disorder with hypomyelination and degenerat

112 our current knowledge as to the function of sphingolipids during plant stress responses, not only as

113 at the infiltration of cholesterols into the sphingolipid-enriched domains plays a crucial roles in t

114 d rafts are tightly packed, cholesterol- and sphingolipid-enriched microdomains within the plasma mem

115 t genetic or pharmacologic modulation of the sphingolipid enzyme DEGS1 regulates lineage differentiat

116 Animal studies suggest vital roles of sphingolipids, especially ceramides, in the pathogenesis

117 Plant sphingolipids exhibit structural differences when compar

118 observed are between lipid categories, with sphingolipids exhibiting 2-6% larger CCSs than glyceroph

119 ysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive mo

120 A role of sphingolipids for inflammatory bowel disease and cancer

121 Here we examined the role of a third sphingolipid, glucosylceramide, in influenza virus infec

122 tissue revealed 132 lipid species, including sphingolipids, glycerophospholipids, and glycerolipids,

123 Sphingolipids have been implicated in mammalian placenta

124 Sphingolipids have important roles in many cellular func

125 Sphingolipids have recently emerged as a biomarker of re

126 Aberrant sphingolipid homeostasis was associated with reduced cel

127 oid-like protein 3 (ORMDL3), which regulates sphingolipid homeostasis, have been strongly linked with

128 ing to additional mechanisms for maintaining sphingolipid homeostasis.

129 data suggest that ACDase deficiency leads to sphingolipid imbalance, inflammation, dysmorphic retinal

130 icular, altered biosynthesis of hydroxylated sphingolipids impaired apical trafficking via Rab11, and

131 nts indicates prominent elevations in plasma sphingolipids in AS progressors that, together with plas

132 nts and lipid mediators, the precise role of sphingolipids in atherosclerosis remains elusive.

133 er, the specific mechanisms and functions of sphingolipids in cell cycle regulation have not been elu

134 These data highlight the role of bacterial sphingolipids in maintaining homeostasis and symbiosis i

135 vasculature by regulating the homeostasis of sphingolipids in mice.

136 asculature by controlling the homeostasis of sphingolipids in mice.

137 pression of human seipin rescued the altered sphingolipids in yeast seipin mutants, suggesting that t

138 Prominent sphingolipids include ceramides and sphingosine-1-phosph

139 Sphingolipids included HBGA-related type 1 chain glycosp

140 nd revealed a variety of Bacteroides-derived sphingolipids including ceramide phosphoinositol and deo

141 Further, we quantified sphingolipids including SM and Ceramide (Cer) using Mult

142 tra-HPLC-tandem MS (UPLC-MS/MS), we measured sphingolipids (including S1P and ceramides) in AML and c

143 mega-9 fatty acid, predominantly acylated to sphingolipids, including ceramides, are selectively redu

144 versely, in liver and serum, levels of total sphingolipids, including ceramides, were increased in Or

145 vely bound several anionic phospholipids and sphingolipids, including phosphatidylserine, ceramide-1-

146 and fetus decreases the placental levels of sphingolipids, including sphingoid bases (sphingosine an

147 We generated a novel sphingolipid-inclusive CAD risk score, termed SIC, that

148 king seipin displayed altered sensitivity to sphingolipid inhibitors, accumulated sphingoid precursor

149 (S1P), a metabolic product of cell membrane sphingolipids, is bound to extracellular chaperones, is

150 These results indicate that AHR up-regulates sphingolipid levels and is important for full axon myeli

151 ce of the regulatory mechanisms that control sphingolipid levels in these processes is not well under

152 ess critical for balancing the intracellular sphingolipid levels needed for growth and programmed cel

153 els was significantly reduced, whereas total sphingolipid levels were not affected.

154 niquely associated with a marked decrease in sphingolipid levels, as well as levels of a number of ot

155 tify genes that positively regulate membrane sphingolipid levels, here we employed a genome-wide CRIS

156 in the number of hydroxylation sites on the sphingolipid long-chain base and the fatty acyl moiety p

157 As such, modulation of sphingolipids may represent a promising avenue of therap

158 vely associated with CAD.RESULTSNearly every sphingolipid measured (n = 30 of 32) was significantly e

159 apeutic effects of AC inhibition in relevant sphingolipid-mediated disorders.

160 Sphingosine 1-phosphate is a bioactive sphingolipid mediator involved in various cellular funct

161 Thus, we identify a sphingolipid metabolic network with a critical role in Z

162 s of a plant immune receptor and that beyond sphingolipid metabolic regulation ORM proteins can also

163 reclinical and clinical studies suggest that sphingolipid metabolism alterations contribute to neurop

164 and represents a tight link between cellular sphingolipid metabolism and immunity.

165 Galc-silenced cells displayed altered sphingolipid metabolism and increased intracellular leve

166 nstrated that there is a correlation between sphingolipid metabolism and KSHV+ tumor cell survival.

167 hingolipid, and protein analyses to evaluate sphingolipid metabolism and signaling post-MI.

168 r whether and how mammalian ORMDL3 regulates sphingolipid metabolism and whether altered sphingolipid

169 , we exploited pharmacological inhibition of sphingolipid metabolism as an option to interfere with p

170 that implicate intracellular trafficking and sphingolipid metabolism as molecular causal mechanisms.

171 is inhibitor, suggesting that alterations in sphingolipid metabolism contribute to cell dysfunction a

172 applied to identify and characterize a human sphingolipid metabolism disorder.

173 Our findings establish that altered sphingolipid metabolism due to GARP mutations contribute

174 mic, and perturbation studies, we found that sphingolipid metabolism in astrocytes triggers the inter

175 way model systems.Objectives: To investigate sphingolipid metabolism in cystic fibrosis and the effec

176 obiotic metabolizing enzymes, and changes in sphingolipid metabolism in differentiated HepaRG.

177 ndicate that the Ormdls function to restrain sphingolipid metabolism in order to limit levels of dang

178 and susceptibility to infection.Conclusions: Sphingolipid metabolism is altered in airway epithelial

179 The influence of sphingolipid metabolism is poorly understood with a lack

180 Disturbance of sphingolipid metabolism may represent a novel therapeuti

181 ect genetic perturbation of the hydroxylated sphingolipid metabolism modulated rhabdomere growth in a

182 Sphingolipid metabolism plays an important role in deter

183 Ceramides are central intermediates of sphingolipid metabolism that also function as potent mes

184 r findings suggest that transiently altering sphingolipid metabolism through AC overexpression is suf

185 Emerging literature links altered sphingolipid metabolism to nociceptive processing.

186 One of the pathways targeted by sphingolipid metabolism turned out to be the secretory r

187 es, including AURKA and CDCA3, controlled by sphingolipid metabolism, and required for PEL survival w

188 To further develop sphingolipid metabolism-targeted therapy, after screenin

189 mide and lactosylceramide indicated impaired sphingolipid metabolism.

190 differential function of enzymes regulating sphingolipid metabolism.

191 amino acid, phenylpropanoid, camalexin, and sphingolipid metabolism.

192 , which are critical regulators of lysosomal sphingolipid metabolism.

193 Pathways including glycerophospholipid and sphingolipid metabolisms were significantly enriched in

194 flections on my adventure with the bioactive sphingolipid metabolite sphingosine-1-phosphate intertwi

195 SphK2) is known to phosphorylate the nuclear sphingolipid metabolite to generate sphingosine-1-phosph

196 Sphingosine-1-phosphate, a bioactive sphingolipid metabolite, is produced by 2 highly conserv

197 inase 1 (SphK1) which produces the bioactive sphingolipid metabolite, sphingosine 1-phosphate (S1P),

198 Finally, we briefly survey the utility of sphingolipid metabolites as potential biomarkers for all

199 ently unknown if deficiency of nervonic acid-sphingolipid metabolites contribute to complications of

200 undantly to suppress the levels of bioactive sphingolipid metabolites during myelination of the sciat

201 In the past few decades, sphingolipids and sphingolipid metabolites have gained attention because o

202 described accumulation of sphingolipids and sphingolipid metabolites, and it has become clear that t

203 ng to the structural integrity of membranes, sphingolipid metabolites, such as sphingosine-1-phosphat

204 Here, we report that ceramide or related sphingolipids might invert the topology of many GPCRs th

205 To determine whether bacterial sphingolipids modulate intestinal health, we colonized g

206 In some cases, large amounts of specific sphingolipids must be synthesized for specialized physio

207 ypes, including the recently published plm-2 sphingolipid mutant.

208 Eleven novel and 3 reported sphingolipids, namely ceramides (d18:1/18:1, d18:1/20:0,

209 from lipid pathways including; ether lipids, sphingolipids (notably GM(3) gangliosides) and lipid cla

210 incident diabetes associated with individual sphingolipids or sphingolipid scores.

211 rkers of CVD and suggests that comprehensive sphingolipid panels should be considered as measures of

212 cosphingolipid synthesis and efflux of Cav-1-sphingolipid particles containing mitochondrial proteins

213 ficant number of enzymatic regulators of the sphingolipid pathway have been described in detail, many

214 ngomyelinase (ASM) is a key regulator of the sphingolipid pathway.

215 gnificant overrepresentation of genes in the sphingolipid pathways that may signify an alternative de

216 demonstrating a role for NS4B in modulating sphingolipid pathways.

217 rdance for synthetic lethality for the yeast sphingolipid phospholipase ISC1, we identified two group

218 hways, including biosynthesis of wax esters, sphingolipids, phospholipids and flavonoids, along with

219 Sphingolipids play important roles in physiology and cel

220 The metabolic network of sphingolipids plays important roles in cancer biology.

221 lic substrates to exert optical control over sphingolipid production in cells.

222 nction of seipin as a negative regulator for sphingolipid production.

223 nt with recombinant human acid ceramidase on sphingolipid profile and inflammatory mediator productio

224 The blood sphingolipid profile in the patient showed a significant

225 y involving over 600 individuals and found a sphingolipid profile that predicted coronary artery dise

226 and established cell lines, that this Cav-1-sphingolipid program evidences a metabolic vulnerability

227 complished a cell-free reconstitution of the sphingolipid regulation of the ORMDL-SPT complex to prob

228 A lack of Bacteroides-derived sphingolipids resulted in intestinal inflammation and al

229 DL3b excess affects the production of active sphingolipids resulting in decreased ceramide-1-phosphat

230 pentose phosphate pathway (PPP), along with sphingolipid (S1P) signaling, activates mTOR and allows

231 n end products (AGEs), phosphatidylcholines, sphingolipids, saturated/unsaturated fatty acids, eicosa

232 metabolism towards a program of 1) exogenous sphingolipid scavenging independent of cholesterol, 2) i

233 chemical structures of individual species, 6 sphingolipid scores were constructed.

234 associated with individual sphingolipids or sphingolipid scores.

235 th the modified cytolysin ALO-D4) but not in sphingolipid-sequestered cholesterol [a pool detectable

236 However, the neuropharmacology of sphingolipid signaling in the central nervous system in

237 support the hypothesis that modification of sphingolipid signaling may be a novel therapeutic approa

238 on TORC2-mediated homeostatic regulation of sphingolipid (SL) metabolism.

239 Ceramides, a type of sphingolipid (SL), have been implicated in the developme

240 ramides (Cer) and cerebrosides are important sphingolipids (SL) involved in many biological processes

241 Sphingolipids (SLs) are chemically diverse lipids that h

242 Sphingolipids (SLs) are structurally diverse lipids that

243 ing to the phylum Bacteroidetes, synthesizes sphingolipids (SLs).

244 we have shown a role for the GARP complex in sphingolipid sorting and homeostasis (Frohlich et al. 20

245 trometry (HRMS) approach to identify various sphingolipid species in breast cancer patients.

246 this complexity, the automated annotation of sphingolipid species is challenging, and incorrect annot

247 ility to detect and correctly annotate novel sphingolipid species make LDA broadly applicable to auto

248 using unbiased machine learning to identify sphingolipid species positively associated with CAD.RESU

249 ent showed a significant increase in dihydro sphingolipid species that was further recapitulated in p

250 can flip a variety of glycerolipids and the sphingolipid sphingomyelin across membranes.

251 on depends on cellular lipids, including the sphingolipids sphingomyelin and sphingosine.

252 The single-chained sphingolipid sphingosine is an essential structural lipi

253 Sphingolipids (SphLs) are a diverse class of molecules t

254 Sphingolipids (SPLs) are the largest class of bioactive

255 1 activator rescues aberrant cholesterol and sphingolipid storage and trafficking in NPC1 mutant cell

256 n Fabry disease (FD), such as low native T1 (sphingolipid storage) and late gadolinium enhancement (L

257 isease, low myocardial T1 values, reflecting sphingolipid storage, are associated with early structur

258 allenges inherent to automated annotation of sphingolipid structures from MS/MS data, we first develo

259 SLs) and cerebrosides (HexCer), constitute a sphingolipid subclass.

260 Furthermore, other bioactive sphingolipids such as ceramide were also down-regulated

261 the numerous lipid subtypes that accumulate, sphingolipids such as ceramides are particularly impactf

262 he Orm-SPT system also directly responded to sphingolipid, suggesting that yeast cells have, in addit

263 a coordinate regulation of ether lipids with sphingolipids, suggesting an adaptation and functional c

264 tic or pharmacological inhibition of de novo sphingolipid synthases prevented diabetes in animal stud

265 human asthma remain unclear, both decreased sphingolipid synthesis and ORMDL3 overexpression are lin

266 ORMDL3 is known to regulate sphingolipid synthesis by binding serine palmitoyltransf

267 , suggesting that the negative regulation of sphingolipid synthesis by seipin is likely an evolutiona

268 een ORMDL3 asthma-risk genotypes and altered sphingolipid synthesis has been lacking.

269 Although the effects of 17q21 genotypes on sphingolipid synthesis in human asthma remain unclear, b

270 a risk and higher ORMDL3 expression to lower sphingolipid synthesis in humans.

271 culture but showed increased sensitivity to sphingolipid synthesis inhibition.

272 are corrected by treatment with myriocin, a sphingolipid synthesis inhibitor, suggesting that altera

273 How sphingolipid synthesis is regulated to fulfill these phy

274 Altered sphingolipid synthesis may therefore be a critical facto

275 eurodegeneration and suggest that inhibiting sphingolipid synthesis might provide a useful strategy f

276 Acutely inhibiting sphingolipid synthesis using myriocin attenuates transpo

277 uction of and cellular dependency on de novo sphingolipid synthesis via PAQR4 highlights a central vu

278 Additionally, de novo sphingolipid synthesis was lower in children with asthma

279 sphingolipid metabolism and whether altered sphingolipid synthesis would be causally related to asth

280 logues in yeast are well-known inhibitors of sphingolipid synthesis, it is still unclear whether and

281 Without proper ORMDL-mediated regulation of sphingolipid synthesis, severe dysmyelination results.

282 onship of genetic asthma susceptibility with sphingolipid synthesis, we analyzed asthma-associated 17

283 ng childhood asthma through dysregulation of sphingolipid synthesis.

284 A recent study now shows that one of the sphingolipids, t18:0 phytoshinganine, binds to PD locali

285 For high-throughput analyses of sphingolipids, tandem mass spectrometry (MS/MS) is the m

286 glycosyl inositol phosphoryl ceramide (GIPC) sphingolipids that are abundant in the outer leaflet of

287 BACKGROUNDCeramides are sphingolipids that play causative roles in diabetes and

288 ing compositions enriched in cholesterol and sphingolipids that undergo continuous remodelling.

289 how that SMPD4 links homeostasis of membrane sphingolipids to cell fate by regulating the cross-talk

290 ose-6-phosphate, and I(1)P(1) generated from sphingolipids, to enable synthesis of IP(6) We also foun

291 idase on inflammation and infection.Methods: Sphingolipids were measured using mass spectrometry in f

292 A total of 43 sphingolipids were quantified and, considering subclasse

293 A total of 76 sphingolipids were quantified using high-coverage target

294 stalline bilayer arrangement of phospho- and sphingolipids, which in turn embeds several proteins and

295 tion of SPT involves a direct interaction of sphingolipid with the membrane-bound components of the S

296 o evaluate prospective associations of serum sphingolipids with incident diabetes in a population-bas

297 to evaluate the associations of circulating sphingolipids with incident T2D and to explore underlyin

298 sted that the detrimental associations of 13 sphingolipids with T2D were largely mediated through bet

299 his study, we observed that a panel of novel sphingolipids with unique structures were positively ass

300 ause adaptive alterations in other bioactive sphingolipids, with pathogenic implications.